Últimas noticias sobre Tenon Medical (NASDAQ:TNON) Bolsa

Tenon Medical

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Tenon Medical Inc

FORT LAUDERDALE, FL / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market.
Everolimus is a generic equivalent of the brand name Afinitor&#xAE;. Everolimus is indicated for the treatment of (i) advanced renal cell carcinoma, (ii) breast cancer in post-menopausal women with advanced HER2-negative genotype, (iii) progressive well or moderately differentiated neuroendocrine tumors of pancreatic, gastrointestinal or lung origin, and (iv) subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Nora Pharma's Everolimus is available in strengths of 2.5 mg, 5 mg, and 10 mg and comes in blister packs of 30 tablets.
According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.1%, reaching around $4.8 billion by 2032. The Canadian segment of the global market is approximately 2.2% and increasing at a compound annual growth rate (CAGR) of 6.4% (IQVIA Pharmafocus 2027).
"Our presence in the industry is propelled by a relentless pursuit of progress," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Through continued investment in cutting-edge technologies, breakthrough research, and strategic partnerships, we are advancing solutions that create lasting impact for patients," he added.

Biotech

News

General

SBFM

Sunshine Biopharma Launches Oncology Drug Everolimus In Canada With An Estimated Global Market Of $2.5B

BGM Group Acquires Wonder Dragon By Issuing 38,165,290 Class A Ordinary Shares At A Price Of $2/Share For Total Transaction Value Of RMB550M

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today is proud to announce that its 5G ORAN Low Power (LPRU) and Mid Power (MPRU) radios have successfully received REACH and RoHS certification. This significant achievement underscores the company's ongoing commitment to environmental responsibility, product quality, and meeting the rigorous regulatory standards required by international markets.
The REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) and RoHS (Restriction of Hazardous Substances) certifications are key industry standards that ensure products are free from harmful substances and comply with European Union environmental regulations. By achieving these certifications, AmpliTech Group affirms its dedication to producing cutting-edge, sustainable, and safe 5G ORAN technology that adheres to the highest environmental standards.

AMPG

AmpliTech Group Achieves REACH And RoHS Certification For Its 5G ORAN Low Power And Mid Power Radios

MainStreet Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSB#NASDAQ">MNSB</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.21 by 19.05 percent. This is a 30.56 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $17.45 million which beat the analyst consensus estimate of $16.36 million by 6.66 percent. This is a 7.29 percent increase over sales of $16.26 million the same period last year.

Earnings

Earnings Beats

MNSB

MainStreet Bancshares Q1 2025 GAAP EPS $0.25 Beats $0.21 Estimate, Sales $17.45M Beat $16.36M Estimate

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC –
– Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+ (CPS ≥10) mTNBC –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy&#xAE; (sacituzumab govitecan-hziy) plus Keytruda&#xAE; (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in PFS.
The safety profile of Trodelvy plus Keytruda in the ASCENT-04 study was consistent with the known safety profile of each agent. No new safety signals were identified with the combination.

GILD

Gilead Sciences: Results From Phase 3 ASCENT-04/KEYNOTE-D19 Study Shows That Trodelvy Plus Keytruda Improved PFS Compared To Keytruda And Chemotherapy In mTNBC Patients

Strategic Collaboration Broadens Across Multiple European Markets
Petah Tikvah, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>, TASE: SVRE)), a technology company specializing in developing transportation safety solutions, today announced the signing of a new commercial agreement with Cemex Czech Republic s.r.o. Under the agreement, SaverOne will deploy its Driver Distraction Prevention System (DDPS) across the entire company-owned cement truck fleet in the Czech Republic.
This new agreement follows a successful and growing collaboration with Cemex throughout Europe. SaverOne's solution has already been implemented across several Cemex entities, among them Israel and an additional European county, and will now be deployed in the Czech Republic with additional deployments planned in further European subsidiaries.

Global

SVRE

SaverOne Expands European Footprint With New Agreement To Deploy Driver Distraction Prevention System Across Cemex Czech Republic's Cement Truck Fleet

RSLS

ReShape Lifesciences Receives Notice Of Allowance From 
USPTO For US Patent Titled 'High-Frequency Low Duty Cycle Patterns for Neural Regulation'

Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it has secured a new order to help modernize the communications infrastructure for a major city in the Nordic region.
Actelis is collaborating with a leading European traffic technology and intelligent transportation systems provider on this order. Through this strategic partnership, Actelis will supply advanced hybrid-fiber networking solutions to enhance connectivity across municipal systems in the second largest city of a prominent Nordic country. This municipality, home to over three hundred thousand residents and part of a metropolitan area exceeding 1.5 million inhabitants, has established itself as a leader in smart city initiatives focused on creating more efficient, sustainable urban infrastructure.

Contracts

ASNS

Actelis Networks Secures Order To Modernize Communications Infrastructure In Major Nordic City Through Strategic Partnership With Leading European Traffic Tech Provider, Supplying Hybrid-Fiber Networking Solutions To Enhance Smart City Connectivity For Over 1.5M Residents

Financing

CSAI

Cloudastructure Secures $3M Investment From Institutional Investor Through Issuance Of Series 2 Convertible Preferred Stock

La Rosa Holdings Corp. (NASDAQ:&nbsp;LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, &nbsp;today announced the successful implementation of its strategic collaboration with Lofty, an AI-powered productivity platform that aims to enhance agent performance and accelerates business growth. The platform supports La Rosa's network of over 2,700 agents while advancing the Company's ongoing national expansion strategy.
Since its launch in November 2024, the Lofty platform has been adopted by over 500 La Rosa agents across the U.S., reflecting strong market demand, swift onboarding, and high user engagement. We believe that the platform's low churn rate underscores its enduring value and strong reception among La Rosa agents. By automating routine tasks and streamlining workflows, Lofty enables La Rosa agents to close more deals, more efficiently—aligning with the Company's long-term growth strategy and commitment to innovation.

LRHC

La Rosa Holdings Enters Strategic Collaboration With Lofty To Increase Agent Productivity And Introduce New Recurring Revenue Stream

On Monday, HIVE Digital Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) disclosed that it completed Phase 1 of infrastructure development at its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/44891819/hive-digital-technologies-announces-100-completion-of-first-100-mw-infrastructure-in-paraguay-and-s" rel="noreferrer noopener">flagship Yguazù facility in Paraguay</a>.
This phase includes a 100-megawatt air-cooled data center supported by a fully operational 200-megawatt substation.
Additionally, the company has appointed Carlos Anibal Torres as its new Operations &amp; Project Manager for Paraguay, a strategic leadership addition as HIVE ramps up growth efforts in the region.
HIVE has finalized the construction and energization of the 100 MW Phase 1 infrastructure at its Yguazù facility, enabling support for up to 5 exahashes per second (EH/s) of next-gen ASIC mining capacity.
Currently, the company is running 200 petahashes of hashrate at the location using its proprietary BUZZ Miners, with plans to have 8,000 units operational by the end of April.
The site has started receiving shipments of advanced ASIC miners, including Bitmain S21+ units, with more than 20,000 expected to arrive by the end of May.
HIVE aims to reach 5 EH/s in Paraguay and a combined total of 11.5 EH/s across all its operations by the close of the second quarter of 2025.
Luke Rossy, Chief Operating Officer of HIVE, said, &#8220;We are executing with conviction. We aim to reach 25 EH/s by Fall 2025, producing over 12 Bitcoins daily at current difficulty levels. With our Paraguay site energized and racking underway, HIVE is positioned for a transformative year of growth.&#8221;
Aydin Kilic, President &amp; CEO of HIVE, added, &#8220;As of March 31, we secured deposits for 4.3 EH/s of Bitmain S21+ miners, funded through disciplined treasury management.&#8221;
In January, the company disclosed that it achieved an operational hashrate of 6.0 Exahashes per second (EH/s), a 47% increase from&nbsp;<a target="_blank" href="https://www.benzinga.com/news/small-cap/25/01/42760447/blockchain-company-hive-digital-achieves-47-hashrate-growth-secures-low-cost-energy-for-mining-in-sweden" rel="noreferrer noopener">4.08 EH/s as of December 31, 2023</a>.
The company plans to expand its global hashrate capacity to 15 EH/s by the end of 2025, achieving a fleet efficiency of 17 joules per terahash (J/TH) through the deployment of its 100 MW <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">hydroelectric-powered expansion in Paraguay</a>.
Price Action: HIVE shares are up 1.34% at $1.51 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/03/44197740/4-bitcoin-stocks-set-for-growth-analyst-highlights-high-performance-computing-as-key-catalyst" target="_blank" rel="noreferrer noopener">4 Bitcoin Stocks Set For Growth: Analyst Highlights High-Performance Computing As Key Catalyst</a></li>
</ul>
Photo by Yalcin Sonat via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Small Cap

Movers

HIVE

HIVE Digital Energizes Paraguay Site With Major Bitcoin Mining Expansion

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/17/final-trades-toast-inc-berkshire-hathaway-citigroup-and-stanley-black-and-decker.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said he remains long on Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) as an investor, and <a href="https://www.benzinga.com/quote/TOST/analyst-ratings">not a trader.</a>
Supporting his view, Wells Fargo analyst Jeff Cantwell upgraded Toast from Underweight to Overweight on April 10 and raised the price target from $30 to $39.
Bill Baruch of Blue Line Capital named Berkshire Hathaway Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) as his final trade ahead of its upcoming earnings report next month.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners said Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) reported positive earnings last week. The company is trading at nine times earnings estimates and has a 3.6% dividend yield, he added.
On April 15, Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $21.60 billion which beat the analyst consensus estimate of $21.29 billion.
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC picked Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) as her final trade.
On the earnings front, Stanley Black &amp; Decker will broadcast its first quarter earnings webcast on Wednesday, April 30. Analysts expect the company to report quarterly earnings at 66 cents per share on revenue of $3.72 billion.
Price Action:
<ul>
<li>Toast shares closed at $34.29 on Thursday.</li>
<li>Berkshire Hathaway gained 0.3% to close at $518.21 during Thursday's session.</li>
<li>Citigroup shares rose 1.9% to close at $63.25 on Thursday.</li>
<li>Stanley Black &amp; Decker shares rose 0.7% to settle at $57.21 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Markets

Media

Trading Ideas

TOST

Citigroup, Berkshire Hathaway, Stanley Black & Decker And More On CNBC's 'Final Trades'

Peter Schiff isn't shy when it comes to <a href="https://www.benzinga.com/25/04/44844540/peter-schiff-china-is-selling-dollars-and-treasuries-to-buy-euros-and-bunds-crashing-the-markets-not-part-of-a-genius-master-plan">challenging conventional wisdom</a> about taxes—or anything else, really.&nbsp;
On Tuesday, the prominent economist <a href="https://x.com/PeterSchiff/status/1912266399398887500">posted</a> on X, quoting his late father Irwin Schiff: &#8220;My father Irwin Schiff always called April 15th the real April Fool&#8217;s Day, as that was the day the IRS fooled millions of Americans into &#8216;voluntarily&#8217; filing income tax returns (what he called confessions) even though no law required anyone to file those returns or pay the tax.&#8221;
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
<h2 class="wp-block-heading">Irwin Schiff's Radical Stance on Taxes</h2>
Irwin Schiff, who died in 2015 at age 87 while serving a 14-year prison sentence for <a href="https://www.benzinga.com/25/02/43850974/its-an-american-duty-to-not-pay-our-taxes-robert-kiyosaki-proudly-says-hes-1-2-billion-in-debt-because-it-legally-leaves-him-tax-free">tax evasion</a>, was one of the most vocal critics of the <a href="https://www.benzinga.com/markets/25/04/44838380/if-you-paid-1-in-federal-income-taxes-you-paid-more-than-tesla-or-amazon-says-bernie-sanders-as-he-takes-on-billionaires-for-tax-inequities">federal income tax</a> in modern American history.&nbsp;
He claimed the tax was unconstitutional and built a national following by teaching others how to avoid it. His books, including &#8220;How Anyone Can Stop Paying Income Taxes&#8221; and &#8220;The Federal Mafia,&#8221; sold more than 250,000 copies, according to <a href="https://www.nytimes.com/2015/10/20/business/yourtaxes/irwin-schiff-fervent-opponent-of-federal-income-taxes-dies-at-87.html">The New York Times</a>, which wrote a sprawling obituary for him.
His argument rested on two key points: First, that the Constitution limited Congress from imposing direct taxes without apportionment, and that the 16th Amendment did not change that. Second, he argued that filling out a tax return violated the Fifth Amendment because any information provided could be used against the filer.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Despite decades of court rulings dismissing these claims, Schiff stuck to his views. He told a federal judge in 1980, &#8220;You, sir, would be the lawbreaker, not I,&#8221; after being sentenced to six months in prison for failing to file returns in 1974 and 1975. He later served additional sentences for promoting tax evasion schemes that the federal government said resulted in $56 million in lost revenue.
<h2 class="wp-block-heading">Peter Schiff Distances Himself</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My father Irwin Schiff always called April 15th the real April Fool&#39;s Day, as that was the day the IRS fooled millions of Americans into &quot;voluntarily&quot; filing income tax returns (what he called confessions) even though no law required anyone to file those returns or pay the tax.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1912266399398887500?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
While Peter Schiff has praised his father&#8217;s intellectual case against the income tax, he's being transparent in that he doesn't follow his father's example. When asked if he files his taxes, Peter responded under his X post: &#8220;Yes, I don&#8217;t want to go to jail for not filing like my father did, so I &#8216;volunteer.'&#8221;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Peter has repeatedly said that the IRS system relies on fear and misdirection. When someone on X pointed to court rulings, like Brushaber v. Union Pacific Railroad Co., Schiff argued that the income tax is technically voluntary, but practically enforced through threats of punishment.
&#8220;The problem is the government goes after you if you don&#8217;t volunteer and the &#8216;courts&#8217; back them up,&#8221; he posted. He also cited 26 U.S. Code 6012(a), claiming his father had legal backing for the idea that &#8220;shall&#8221; in tax law actually means &#8220;may.&#8221;
Whether people see April 15 as a civic duty or a government overreach, the debate sparked by the Schiffs continues to stir strong opinions.
Read Next:
<ul>
<li>With high-demand properties in the Midwest, Bam Capital has delivered 2.46x equity multiples in just over 3 years. No losses. No missed payments. <a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">Learn more about becoming an investor today</a>. </li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

'The Real April Fool's Day Is April 15th,' Says Peter Schiff, Quoting His Tax-Resisting Father On How The IRS Duped America

As market volatility grew and the Nasdaq 100 approached bear-market status, an intriguing pattern emerged: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44779772/gen-z-and-crypto-how-younger-generations-are-weighing-risk-in-investing">investors bet bigger on risk</a>. 
Outstanding shares in the top 50 leveraged ETFs have risen 20% since April 2, according to Citi Global Markets, cited by Bloomberg. 
The day marked President Donald Trump&#8216;s so-called &#8220;Liberation Day&#8221; declaration, which sparked tariff tensions. Even with the uncertainty, retail traders seem unfazed, piling into the high-adrenaline universe of leveraged exchange-traded funds (ETFs) in a daring attempt to reap outsized returns.
<h2 class="wp-block-heading">High Risk, Higher Conviction</h2>
Leveraged ETFs, which derive their returns through derivatives to double, triple, or quadruple an underlying index or asset daily, are experiencing an explosion of popularity. While warning of wipeouts should the market move against the trades, aggressive investors have been attracted to them as the ultimate dip-buying tools.
Nowhere is that sense of optimism stronger than in the following three ETFs that have become default vehicles for the aggressive:
ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>)
<ul>
<li>Leverage: 3x Long Nasdaq-100</li>
<li>The poster child of leveraged dip-buying, TQQQ has attracted around <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/44824856/retail-traders-rush-into-leveraged-tech-etfs-betting-on-nasdaq-rebound-after-sharp-drop">$7.1 billion in net inflows since mid-February</a>, $3.1 billion of which came in following the tariff announcements in early April. Aimed to triple the daily return of the tech-heavy Nasdaq 100, TQQQ dropped more than 50% earlier this year but has since recovered almost 30% from its April 9 low.</li>
<li>Despite a 45% decline from its February high, the rampant buying indicates increased risk appetite as investors hope for another tech-led recovery.</li>
</ul>
Direxion Daily Semiconductor Bull 3x Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXL#NYSE">SOXL</a>)
<ul>
<li>Leverage: 3x Long Semiconductor Index</li>
<li>While the semiconductor industry rides another bumpy cycle, investors are piling into SOXL in hopes that AI demand and supply chain normalization will reignite chip stocks. The ETF brought in $1.8 billion last week alone, <a href="https://www.bloomberg.com/news/articles/2025-04-17/day-traders-refuse-to-give-up-favorite-obsession-leveraged-funds?sref=TBDibEcD">per </a>Bloomberg.</li>
<li>SOXL is designed to provide three times the daily performance of the PHLX Semiconductor Index. Although this leverage amplifies losses as well as gains, it has not dissuaded investors looking for the next big move higher in Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and other semiconductor players.</li>
</ul>
ProShares UltraPro S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPRO#NYSE">UPRO</a>)
<ul>
<li>Leverage: 3x Long S&amp;P 500</li>
<li>While the Nasdaq gets all the headlines, UPRO provides three times exposure to the broad S&amp;P 500—a good bet for those playing a broad-based rebound. The ETF took in $633 million last week, Bloomberg reported.</li>
<li>Even as the wider S&amp;P slid under the weight of tariffs, investors just kept coming in, indicating that most view the drawdown as a buying opportunity, not as a reason to run.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/04/44866215/exclusive-defiance-letting-you-go-2x-long-on-quantum-2x-short-on-ai-straight-from-the-ceo">EXCLUSIVE: Why Defiance Is Letting You Go 2X Long On Quantum, And 2X Short On AI, Straight From The CEO</a>
<h2 class="wp-block-heading">Volatility As A Feature, Not A Bug</h2>
Despite warnings from figures like hedge fund titan Bill Ackman, who recently decried leveraged funds for &#8220;driving dramatic market moves,&#8221; their popularity remains undiminished. Citi analysts note that while retail volumes broadly dipped, leveraged ETFs were an exception, with six making the top 25 most-traded list on Interactive Brokers.
Demand for leveraged ETFs reflects a change in retail investing psychology: volatility is not something to hedge but profit from.
The increased leveraged ETF inflows during a market retreat say it all. Retail traders, some who got their start during the meme stock boom and the 2022 bear market, are growing more comfortable with high-conviction, high-risk bets.
Though the ride is frightening; TQQQ declined 80% in the previous bear cycle before its record-breaking rally; the reward potential brings traders back for more.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44891004/meet-the-key-five-people-who-are-shaping-trumps-economic-agenda">Meet the Key Five People Who Are Shaping Trump&#8217;s Economic Agenda</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

ETFs

NVDA

SOXL

TQQQ

UPRO

3 High-Risk ETFs Aggressive Retail Investors Can't Stop Buying

DA Davidson analyst Michael Shlisky maintains Alamo Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALG#NYSE">ALG</a>) with a Buy and lowers the price target from $217 to $195.

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Alamo Group, Lowers Price Target to $195

Seaport Global analyst Michael Harrison maintains Materion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) with a Buy and lowers the price target from $130 to $120.

MTRN

Seaport Global Maintains Buy on Materion, Lowers Price Target to $120

DA Davidson analyst Michael Shlisky downgrades Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) from Buy to Neutral.

Downgrades

DA Davidson Downgrades Timken to Neutral

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 5.04%</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and cut the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On April 14, Bristol Myers Squibb announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="913" height="853" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32.png" alt="" class="wp-image-879019" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025025/image-32-768x718.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 6.35%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 69%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and lowered the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">VTRS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="913" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33.png" alt="" class="wp-image-879022" style="width:616px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33.png 913w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025258/image-33-768x708.png 768w" sizes="(max-width: 913px) 100vw, 913px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul>
<li>Dividend Yield: 4.15%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $125 to $115 on Feb. 5, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On April 15, Merck and privately held Cyprumed GmbH signed a non-exclusive license and option agreement on Tuesday to develop oral formulations of Merck&#8217;s peptides using Cyprumed&#8217;s drug delivery technology.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13.png" alt="" class="wp-image-879028" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21025652/image-1-13-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

VTRS

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 1% on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell sharply in today's pre-market trading  following a report indicating the company postponed the US debut of an affordable version of its <a href="https://www.benzinga.com/quote/TSLA">Model Y SUV</a>.
Tesla shares dipped 3.9% to $232.08 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>American Assets Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAT#NYSE">AAT</a>) shares dipped 58% to $8.01 in pre-market trading. American Assets Trust will announce its first quarter earnings after the market closes on Tuesday, April 29.</li>
<li>Viavi Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) tumbled 44.2% to $5.50 in pre-market trading.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) fell 12% to $7.25 in pre-market trading after gaining around 44% on Thursday.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) shares slipped 8.3% to $15.01 in pre-market trading.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares fell 7% to $12.51 in pre-market trading.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) declined 6.3% to $19.11 in pre-market trading. Concentra&#xAE; Group Holdings Parent will release the financial results for its first quarter on Wednesday, May 7, after the closing bell.</li>
<li>First Financial Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) fell 5.1% to $31.00 in pre-market trading. Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained First Finl Bankshares with a Market Perform and lowered the price target from $38 to $36.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 3.1% to $98.36 in pre-market trading following a 3% decline on Thursday.</li>
<li>MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>) slipped 3% to $8.50 in pre-market trading.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) declined 2.8% to $7.67 in pre-market trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) slipped 2.3% to $192.51 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44862261/top-3-materials-stocks-that-are-ticking-portfolio-bombs">Top 3 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

AAPL

CGEM

EWTX

FFIN

MTAL

TSLA

VIAV

Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Seaport Global analyst Michael Harrison reiterates Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>) from Neutral to Neutral.

Reiteration

Seaport Global Reiterates Neutral on Lindeto Neutral

Press Releases

Tenon Medical Reports Third Quarter 2024 Financial Results

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office

Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds

Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion

Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors

Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Comments

Tenon Medical

Noticias

Últimas noticias sobre Tenon Medical (NASDAQ:TNON) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL